Gapping up
In reaction to strong earnings/guidance:
- FLNT +39.7% (raises FY19 revenue guidance), OGI +24.5%, ACOR +2.6%, BLK +0.7%
M&A news:
- POPE +24.3% (to be acquired by Rayonier (RYN))
Other news:
- RMTI +12.9% (enters license and supply agreements with Sun Pharma to commercialize Triferic in India)
- EXPR +1.9% (announces restructuring of its corporate workforce)
- GSK +1% (Dovato the once-daily, single-pill, 2drug regimen for the treatment of HIV-1 infection, granted marketing approval by Japan Ministry of Health, Labour and Welfare
- ATHX +0.7% (names Ivor Macleod CFO)
Analyst comments:
- MNTA +14.4% (upgraded to Overweight from Neutral at JP Morgan)
- PCG +5.3% (upgraded to Buy from Neutral at Citigroup)
- GLUU +2.4% (resumed with an Overweight at KeyBanc Capital Markets)
- APHA +2.2% (upgraded to Neutral from Sector Underperform at CIBC)
- ECHO +1.9% (upgraded to Positive from Neutral at Susquehanna)
- MAXR +1.9% (upgraded to Neutral from Underperform at Credit Suisse)
- ZUO +1.7% (initiated with a Outperform at First Analysis Sec)
- CHRW +1.7% (upgraded to Positive from Neutral at Susquehanna; upgraded to Overweight from Equal Weight at Barclays)
- HUN +1.6% (initiated with a Buy at BofA/Merrill)
- WERN +1.4% (upgraded to Positive from Neutral at Susquehanna)
- OCSL +1.3% (upgraded to Overweight from Equal Weight at Wells Fargo)
- ZNGA +1.2% (resumed with an Overweight at KeyBanc Capital Markets)
- B +1% (upgraded to Buy from Neutral at UBS)
- CW +1% (upgraded to Buy from Neutral at UBS)
- PTON +1% (initiated with an Outperform at Wedbush)
- QCOM +0.7% (upgraded to Buy from Hold at DZ Bank)